May 22, 2024
A doctor was sentenced to three months in prison Wednesday for insider trading on an Alexion Pharmaceuticals acquisition, with a Manhattan federal judge saying the defendant's treatment of critically ill, underserved kidney disease patients does not amount to a "get out of jail free card."
May 13, 2024
The former police chief of a town in Massachusetts was sentenced Monday to three months in prison after pleading guilty to trading on confidential information about a pending Alexion Pharmaceuticals merger that he said was provided by a "lifelong friend."
January 23, 2024
A Massachusetts town's former police chief told a Manhattan federal judge Tuesday that he unlawfully profited from secret information about a healthcare-sector merger provided to him by a "lifelong friend," pleading guilty to insider trading charges.
January 05, 2024
A Manhattan federal judge sentenced a former Alexion Pharmaceuticals Inc. vice president to eight months of house arrest Friday for tipping off a childhood friend about the company's $1.4 billion purchase of Portola Pharmaceuticals in 2020, rejecting prosecutors' bid for prison time.
November 27, 2023
A Manhattan federal judge set a May 2024 trial date Monday for the last two defendants to deny their participation in an alleged five-man insider trading ring revolving around Alexion Pharmaceuticals Inc.'s $1.4 billion purchase of another biotech firm.
September 19, 2023
A medical doctor copped to profiting from secrets he learned from a friend about a biotech merger, agreeing to forfeit $472,000 as the Manhattan U.S. attorney's office got a third conviction in an alleged insider trading conspiracy with five defendants.
September 15, 2023
A former Alexion Pharmaceuticals Inc. vice president pled guilty in New York federal court Friday to tipping off a childhood friend about the company's $1.4 billion purchase of another biotech firm in 2020.
June 29, 2023
A former Alexion Pharmaceuticals Inc. executive, his police chief buddy and two doctors were arrested Thursday for alleged insider trading on Alexion's $1.4 billion purchase of another biotech firm in 2020, part of a larger fraud crackdown by the Manhattan U.S. Attorney's Office.